ArticleJournal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer2016
Activating Photodynamic Therapy in vitro with Cerenkov Radiation Generated from Yttrium-90.
Article in Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Radiation activated photodynamic therapy (radioPDT) induces lipid peroxidation and vascular mediated tumor regression of prostate cancer.Scientific reports · 2025Article
- Radionuclide-labelled nanoparticles for cancer combination therapy: a review.Journal of nanobiotechnology · 2024Review
- Engineering photodynamics for treatment, priming and imaging.Nature reviews bioengineering · 2024Article
- Imaging assessment of photosensitizer emission induced by radionuclide-derived Cherenkov radiation using charge-coupled device optical imaging and long-pass filters.World journal of radiology · 2023Article
- Added Value of Scintillating Element in Cerenkov-Induced Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Review
- Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma.Scientific reports · 2022Article
- Photoactivation of Chemotherapeutic Agents with Cerenkov Radiation for Chemo-Photodynamic Therapy.ACS omega · 2022Article
- Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2021Review
- Application of TD-DFT Theory to Studying Porphyrinoid-Based Photosensitizers for Photodynamic Therapy: A Review.Molecules (Basel, Switzerland) · 2021Review
- Review
- Nanoparticles for Cerenkov and Radioluminescent Light Enhancement for Imaging and Radiotherapy.Nanomaterials (Basel, Switzerland) · 2020Review
- Radiodynamic therapy using 15-MV radiation combined with 5-aminolevulinic acid and carbamide peroxide for prostate cancer in vivo.Physics in medicine and biology · 2020Article
- Radionuclide-Activated Nanomaterials and Their Biomedical Applications.Angewandte Chemie (International ed. in English) · 2019Review
- Nanoparticles to mediate X-ray-induced photodynamic therapy and Cherenkov radiation photodynamic therapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Radioluminescence in biomedicine: physics, applications, and models.Physics in medicine and biology · 2019Review
- Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging.Seminars in nuclear medicine · 2018Review
- Nanoparticles as multimodal photon transducers of ionizing radiation.Nature nanotechnology · 2018Article
- Reply to 'Is Cherenkov luminescence bright enough for photodynamic therapy?'Nature nanotechnology · 2018Article
- When radionuclides meet nanoparticles.Nature nanotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The translation of photodynamic therapy (PDT) to the clinical setting has primarily been limited to easily accessible and/or superficial diseases, for which traditional light delivery can be performed noninvasively. Cerenkov radiation, as generated from medically relevant radionuclides, has been suggested as a means to deliver light to deeper tissues noninvasively to overcome this depth limitation. This article investigates the utility of Cerenkov radiation, as generated from the radionuclide yttrium-90, for activating the PDT process using clinically approved aminolevulinic acid at 1.0 mm and also the more efficient porphyrin-based photosensitizer mesotetraphenylporphine with two sulfonate groups on adjacent phenyl rings (TPPS2a) at 1.2 µm. Experiments were conducted with monolayer cultured glioma and breast tumor cell lines. Although aminolevulinic acid proved to be ineffective for generating a therapeutic effect at all but the highest activity levels, TPPS2a produced at least a 20% therapeutic effect at activities ranging from 6 to 60 µCi/well for the C6 glioma cell line. Importantly, these results demonstrate for the first time, to our knowledge, that Cerenkov radiation generated from a radionuclide can be used to activate PDT using clinically relevant photosensitizers. These results therefore provide evidence that it may be possible to generate a phototherapeutic effect in vivo using Cerenkov radiation and clinically relevant photosensitizers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.